The quality troubles that Pfizer acquired with Hospira this month are symptoms of an aging, shortage-prone sterile injectables infrastructure that the pharmaceutical industry is preparing to resolve with new, more agile manufacturing facilities.
Pfizer is piloting a modular oral solids manufacturing system that could be adapted for sterile injectables even as other manufacturers are working to resolve the challenges of the aging sterile injectable facilities they recently acquired Also see "
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?